DOCSLIB.ORG

B Cell Activation Factor (BAFF) Is a Novel Adipokine That Links Obesity and Inflammation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
B Cell Activation Factor (BAFF) Is a Novel Adipokine That Links Obesity and Inflammation EXPERIMENTAL and MOLECULAR MEDICINE, Vol. 41, No. 3, 208-216, March 2009 B cell activation factor (BAFF) is a novel adipokine that links obesity and inflammation Yu-Hee Kim1, Bong-Hyuk Choi1, pression of TACI was distinct from that of BAFF-R and Hyae-Gyeong Cheon2 and Myoung-Sool Do1,3 BCMA under TNF-α and BAFF ligand treatment. BAFF-R and BCMA expression levels were upregu- 1School of Life and Food Sciences lated under pro-inflammatory conditions, but TACI Handong Global University was reduced. Conversely, BAFF-R and BCMA ex- Pohang 791-708, Korea pression levels were downregulated by rosiglitazone 2Center for Metabolic Syndrome Therapeutics treatment, but TACI was increased. Taken together, Drug Discovery Division our results suggest that BAFF may be a new adipokine, Korea Research Institute of Chemical Technology representing a link between obesity and inflammation. Daejeon 305-343, Korea 3Corresponding author: Tel, 82-54-260-1301; Keywords: adipokine; B-cell maturation antigen; obe- Fax, 82-54-260-1319; E-mail, [email protected] sity; rosiglitazone; TNFRSF13C protein, human; DOI 10.3858/emm.2009.41.3.024 TNFSF13B protein, human; transmembrane activator and CAML Interactor protein Accepted 18 November 2008 Abbreviations: BAFF, B cell activation factor; BAFF-R, BAFF Introduction receptor; BCMA, B cell maturation antigen; BCS, bovine calf serum; BLyS, B lymphocyte stimulator; CCL, CC chemokine ligand; COX, B cell activation factor (BAFF) was recently intro- cyclooxygenase; CRP, C-reactive protein; EAT, epididymal adipose duced as a novel member of the TNF ligand tissue; ECL, enhanced chemiluminescence; IBMX, methylisobutyl- superfamily and is also named BLyS, THANK, xanthine; MCP-1, monocyte chemotatic protein-1; PAI-1, plas- TALL-1, and TNFSF13B (Moore et al., 1999; minogen activator inhibitor-1; SAA, serum amyloid A; TACI, trans- Nardelli et al., 2001). BAFF is a type II transmem- membrane activator and CAML interactor; TALL-1, TNF- and ApoL- brane protein, containing 285 amino acids. The related leukocyte-expressed ligand 1; THANK, TNF homologue that soluble form of BAFF, cleaved by "furin-like" pro- activates apoptosis, NF-kB, and JNK; TNFSF13B, TNF superfamily tease, is a 152 amino acid protein, with a mass of 13B; VAT, visceral adipose tissue 17,038 daltons (Moore et al., 1999). BAFF is produced by myeloid lineage cells, malignant B cells, activated T cells, and bone marrow stromal Abstract cells (Nardelli et al., 2001; Novak et al., 2002; Scapini et al., 2003; Lavie et al., 2004). The B cell activation factor (BAFF) is a novel member of the recombinant soluble BAFF (aa 134-285) binds spe- TNF ligand superfamily, mainly produced by myeloid cifically to human primary B cells and B cell tumor cells. BAFF has been shown to participate in B-cell sur- lines, but not to T cells, monocytes, NK cells, or vival and B- and T-cell maturation. BAFF expression in granulocytes (Moore et al., 1999). adipocytes has been recently demonstrated. In the cur- BAFF has three receptors that belong to the TNF rent study, we verified that BAFF expression is in- receptor superfamily: B cell maturation antigen creased during adipocyte differentiation. BAFF ex- (BCMA), transmembrane activator and CAML pression was augmented by TNF-α treatment and was interactor (TACI), and BAFF receptor (BAFF-R) decreased by rosiglitazone treatment. BAFF secretion (Gross et al., 2000; Thompson et al., 2001). These in lean and in ob/ob mice sera were compared and receptors are primarily expressed in B cells, but TACI and BAFF-R are known to be expressed by T smaller amount of BAFF was secreted in ob/ob mice. cell subsets as well (Huard et al., 2001; Ng et al., mRNA and protein expression were different between 2004). Because of the receptor distribution, the epididymal and visceral adipose tissue. BAFF ex- studies on BAFF have been focused on B cells pression was also increased in ob/ob mouse adipose and T cells. It has been shown that BAFF is res- tissue. We sought to identify known BAFF receptors ponsible for B cell survival and maturation (Mackey (BAFF-R, BCMA, and TACI) in adipocytes, and de- et al., 1999; Craxton et al., 2003), and also func- termined that all three were present and upregulated tions as a T-cell co-stimulatory molecule (Huard et during adipocyte differentiation. However, the ex- al., 2001; Ng et al., 2004). Furthermore, overexpre- BAFF linking obesity and inflammation 209 ssion of BAFF results in autoimmune-like manifes- obesity and related diseases. tations (Mackey et al., 1999), and BAFF levels are Previously, we have investigated the expression elevated in human autoimmune diseases such as profiles of inflammatory genes in human SGBS systemic lupus erythematosus, rheumatoid arthritis, adipocytes using DNA microarrays, and found that and multiple myeloma (Zhang et al., 2001; Novak TNFSF13B (another term for BAFF) is also et al., 2004; Seyler et al., 2005). The expression expressed by human adipocytes. We reported that and functional effects of BAFF on other cell linea- TNFST13B expression is increased during adipo- ges have not been elucidated. cyte differentiation and TNF-α treatment (Do et al., Adipose tissue has long been known to provide 2006). Recently, Pelekanou and his coworkers energy storage for the body, but recent studies have reported the expression of BAFF in breast have resulted in redefinition of this tissue as an tumor lesions and also in adipocytes surrounding endocrine organ (Mohamed-Ali et al., 1998). Adi- the tumor lesions (Pelekanou et al., 2008). We pose tissue causes inflammation by secreting were therefore interested in further examination of cytokines (such as TNF-α and IL-6), chemokines BAFF expression in adipocytes. (CCL2; MCP-1), and acute-phase molecules (CRP, In adipocytes, secreted TNF acts on cells via an haptoglobin, SAA, PAI-1) (Fantuzzi et al., 2005; autocrine/paracrine pathway through TNFR1 acti- Kim et al., 2006). Moreover, the adipokines, speci- vation (Nguyen et al., 2005). Additionally, it has fic cytokines that are mainly produced by adipo- been reported that BAFF and BAFF receptors are cytes e.g. leptin, adiponectin, and resistin, are co-expressed by B cells, and that BAFF may signal increasingly being shown to have important roles through an autocrine pathway as a member of the as mediators linking the adipose tissue and infla- TNF ligand superfamily (Haiat et al., 2006). There- mmation (Fantuzzi et al., 2005; Kim et al., 2006; fore, verification of the existence of BAFF recep- Tilg et al., 2006). Obesity, now considered to be a tors on adipocytes may lead to a greater unders- low-grade chronic inflammation state, increases tanding of the function of BAFF in adipocytes. the risk of many metabolic diseases such as type 2 Here we provide the first report of the expression diabetes, atherosclerosis, certain cancers, and au- of BAFF and BAFF receptors in 3T3-L1 adipocytes. toimmune diseases (Wisse et al., 2004; Fantuzzi et We examined mRNA and protein expression levels al., 2005; Kim et al., 2006; Tilg et al., 2006). The of BAFF during adipocyte differentiation, and their dysregulation of adipokine secretion is often changes under pro-inflammatory and anti-inflam- observed in patients with obesity; therefore, adipo- matory conditions. We also examined the existence kines may provide a link between obesity and of BAFF receptors on 3T3-L1 adipocytes and metabolic disorders. In this regard, further research observed their changes in response to induction or into the identification and characterization of novel inhibition of inflammation. BAFF and BAFF receptor adipokines will improve our understanding of expression in adipose tissue of ob/ob transgenic Figure 1. BAFF expression during adipocyte differentiation. (A) The relative amount of BAFF gene expression was evaluated by real time RT-PCR on ev- ery other day of 3T3-L1 adipocyte differentiation (*P ＜ 0.05). (B) The relative amount of BAFF protein was evaluated by western blot analysis on every other day of 3T3-L1 adipocyte differentiation. Data are expressed relative to untreated control cells and represent means ± S.E. Experiments were con- ducted twice, each included triplication. 210 Exp. Mol. Med. Vol. 41(3), 208-216, 2009 mice was examined as well. We further investigated 3T3-L1 adipocytes on every other day during the the autocrine effects on 3T3-L1 adipocytes by progression of differentiation. We examined mRNA treatment with soluble BAFF protein and examined and protein expression levels of BAFF using real the changes of BAFF receptors expression. time RT-PCR and western blot analysis, respec- tively. BAFF mRNA expression levels were increa- sed as differentiation progressed, and were aug- Results mented 1.7-fold after six days of differentiation (Figure 1A). Similarly, protein expression levels BAFF expression is increased during adipocyte were increased in accordance with differentiation, differentiation and on day six of differentiation BAFF protein level In order to determine whether BAFF expression is was 1.5-fold higher than before the induction of affected by adipocyte differentiation, we collected differentiation (Figure 1B). Figure 2. Changes of BAFF expression by TNF-α and Rosiglitazone treatment. (A) The relative amount of BAFF gene expression was evaluated by real time RT-PCR at different time points after simulation with 10 ng/ml TNF-α (*P ＜ 0.05, **P ＜ 0.01, ***P ＜ 0.001). (B) The relative amount of BAFF pro- tein was evaluated by western blot analysis at different time points after simulation with 10 ng/ml TNF-α. (C) The relative amount BAFF gene expression was evaluated by real time RT-PCR at different time points after simulation with 1.5 μM Rosiglitazone (*P ＜ 0.05, **P ＜ 0.01). (D) The relative amount of BAFF protein was evaluated by western blot analysis at different time points after simulation with 1.5 μM Rosiglitazone. Data are expressed relative to untreated control cells and represent means ± S.E.
Load more

Recommended publications
  • Cells Promote Survival and Differentiation of B Up-Regulated In
    Expression of the Adaptor Protein Hematopoietic Src Homology 2 is Up-Regulated in Response to Stimuli That Promote Survival and Differentiation of B This information is current as Cells of September 28, 2021. Brantley R. Herrin and Louis B. Justement J Immunol 2006; 176:4163-4172; ; doi: 10.4049/jimmunol.176.7.4163 http://www.jimmunol.org/content/176/7/4163 Downloaded from References This article cites 48 articles, 23 of which you can access for free at: http://www.jimmunol.org/content/176/7/4163.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 28, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2006 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Expression of the Adaptor Protein Hematopoietic Src Homology 2 is Up-Regulated in Response to Stimuli That Promote Survival and Differentiation of B Cells Brantley R. Herrin and Louis B. Justement1 Analysis of hematopoietic Src homology 2 (HSH2) protein expression in mouse immune cells demonstrated that it is expressed at low levels in resting B cells but not T cells or macrophages.
    [Show full text]
  • Antagonist Antibodies Against Various Forms of BAFF: Trimer, 60-Mer, and Membrane-Bound S
    Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2016/07/19/jpet.116.236075.DC1 1521-0103/359/1/37–44$25.00 http://dx.doi.org/10.1124/jpet.116.236075 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 359:37–44, October 2016 Copyright ª 2016 by The American Society for Pharmacology and Experimental Therapeutics Unexpected Potency Differences between B-Cell–Activating Factor (BAFF) Antagonist Antibodies against Various Forms of BAFF: Trimer, 60-Mer, and Membrane-Bound s Amy M. Nicoletti, Cynthia Hess Kenny, Ashraf M. Khalil, Qi Pan, Kerry L. M. Ralph, Julie Ritchie, Sathyadevi Venkataramani, David H. Presky, Scott M. DeWire, and Scott R. Brodeur Immune Modulation and Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut Received June 20, 2016; accepted July 18, 2016 Downloaded from ABSTRACT Therapeutic agents antagonizing B-cell–activating factor/B- human B-cell proliferation assay and in nuclear factor kB reporter lymphocyte stimulator (BAFF/BLyS) are currently in clinical assay systems in Chinese hamster ovary cells expressing BAFF development for autoimmune diseases; belimumab is the first receptors and transmembrane activator and calcium-modulator Food and Drug Administration–approved drug in more than and cyclophilin ligand interactor (TACI). In contrast to the mouse jpet.aspetjournals.org 50 years for the treatment of lupus. As a member of the tumor system, we find that BAFF trimer activates the human TACI necrosis factor superfamily, BAFF promotes B-cell survival and receptor. Further, we profiled the activities of two clinically ad- homeostasis and is overexpressed in patients with systemic vanced BAFF antagonist antibodies, belimumab and tabalumab.
    [Show full text]
  • Haptoglobin and Its Related Protein, Zonulin—What Is Their Role in Spondyloarthropathy?
    Journal of Clinical Medicine Review Haptoglobin and Its Related Protein, Zonulin—What Is Their Role in Spondyloarthropathy? Magdalena Chmieli ´nska 1,2,* , Marzena Olesi ´nska 2, Katarzyna Romanowska-Próchnicka 1,2 and Dariusz Szukiewicz 1 1 Department of Biophysics and Human Physiology, Medical University of Warsaw, Chałubi´nskiego5, 02-004 Warsaw, Poland; [email protected] (K.R.-P.); [email protected] (D.S.) 2 Department of Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, Sparta´nska1, 02-637 Warsaw, Poland; [email protected] * Correspondence: [email protected] Abstract: Haptoglobin (Hp) is an acute phase protein which supports the immune response and protects tissues from free radicals. Its concentration correlates with disease activity in spondy- loarthropathies (SpAs). The Hp polymorphism determines the functional differences between Hp1 and Hp2 protein products. The role of the Hp polymorphism has been demonstrated in many diseases. In particular, the Hp 2-2 phenotype has been associated with the unfavorable course of some inflammatory and autoimmune disorders. Its potential role in modulating the immune system in SpA is still unknown. This article contains pathophysiological considerations on the potential relationship between Hp, its polymorphism and SpA. Keywords: haptoglobin polymorphism; inflammation; pathogenesis; spondyloarthropathy; zonulin Citation: Chmieli´nska,M.; Olesi´nska, M.; Romanowska-Próchnicka, K.; Szukiewicz, D. Haptoglobin and Its 1. Introduction Related Protein, Zonulin—What Is Spondyloarthropathy is one of the most common rheumatic diseases whose prevalence Their Role in Spondyloarthropathy? J. varies between 0.4 and 1.9% in different countries [1]. The heterogeneity of SpA is the Clin. Med. 2021, 10, 1131.
    [Show full text]
  • Downloaded from Bioscientifica.Com at 09/25/2021 07:25:24AM Via Free Access 812 M Andreassen and Others EUROPEAN JOURNAL of ENDOCRINOLOGY (2012) 166
    European Journal of Endocrinology (2012) 166 811–819 ISSN 0804-4643 CLINICAL STUDY GH activity and markers of inflammation: a crossover study in healthy volunteers treated with GH and a GH receptor antagonist Mikkel Andreassen1, Jan Frystyk2,3, Jens Faber1,4 and Lars Østergaard Kristensen1 1Endocrine Unit, Laboratory of Endocrinology 54o4, Department of Internal Medicine O, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, DK-2730 Herlev, Denmark, 2Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark and 3Medical Research Laboratories, Faculty of Health Sciences, Institute of Clinical Medicine, Aarhus University, Aarhus, Denmark and 4Faculty of Health Science, Copenhagen University, Copenhagen, Denmark (Correspondence should be addressed to M Andreassen; Email: [email protected]) Abstract Introduction: The GH/IGF1 axis may modulate inflammatory processes. However, the relationship seems complicated as both pro- and anti-inflammatory effects have been demonstrated. Methods/design: Twelve healthy volunteers (mean age 36, range 27–49 years) were treated in random order with increasing doses of GH for 3 weeks (first week 0.01 mg/kg per day, second week 0.02 mg/kg per day, and third week 0.03 mg/kg per day) or a GH receptor antagonist (pegvisomant; first week 10 mg/day and last two weeks 15 mg/day), separated by 8 weeks of washout. Circulating levels of the pro-inflammatory cytokines tumor necrosis factor a (TNFa (TNFA)), interleukin 6 (IL6), and IL1b (IL1B) and the acute phase proteins (APPs) C-reactive protein (CRP), haptoglobin, orosomucoid, YKL40 (CHI3L1), and fibrinogen were measured. Results: During GH treatment, IGF1 (median 131 (Inter-quartile range (IQR) 112–166) vs 390 (322– 524) mg/l, PZ0.002) increased together with TNFa (0.87 (0.74–1.48) vs 1.27 (0.80–1.69) ng/l, PZ0.003), IL6 (1.00 (0.83–1.55) vs 1.35 (0.80–4.28) ng/l, PZ0.045), and fibrinogen (9.2 (8.8–9.6) vs 11.1 (9.4–12.4) mM, PZ0.002).
    [Show full text]
  • Downloaded and Further Processed with the R Programming Language ( and Bioconductor ( Software
    bioRxiv preprint doi: https://doi.org/10.1101/801530; this version posted October 13, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. An integrated multi-omic single cell atlas to redefine human B cell memory David R. Glass,1,2,5 Albert G. Tsai,2,5 John Paul Oliveria,2,3 Felix J. Hartmann,2 Samuel C. Kimmey,2,4 Ariel A. Calderon,1,2 Luciene Borges,2 Sean C. Bendall1,2,6,* 1Immunology Graduate Program, Stanford University, Stanford, CA, 94305, USA 2Department of Pathology, Stanford University, Stanford, CA, 94305, USA 3Department of Medicine, Division of Respirology, McMaster University, Hamilton, ON, L8S4K1, Canada 4Department of Developmental Biology, Stanford, University, Stanford CA, 94305, USA 5Co-first author 6Lead Author *Correspondence: [email protected] bioRxiv preprint doi: https://doi.org/10.1101/801530; this version posted October 13, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. Abstract: To evaluate the impact of heterogeneous B cells in health and disease, comprehensive profiling is needed at a single cell resolution. We developed a highly- multiplexed screen to quantify the co-expression of 351 surface molecules on low numbers of primary cells. We identified dozens of differentially expressed molecules and aligned their variance with B cell isotype usage, metabolism, biosynthesis activity, and signaling response.
    [Show full text]
  • Targeting Costimulatory Molecules in Autoimmune Disease
    Targeting costimulatory molecules in autoimmune disease Natalie M. Edner1, Gianluca Carlesso2, James S. Rush3 and Lucy S.K. Walker1 1Institute of Immunity & Transplantation, Division of Infection & Immunity, University College London, Royal Free Campus, London, UK NW3 2PF 2Early Oncology Discovery, Early Oncology R&D, AstraZeneca, Gaithersburg, MD, USA 3Autoimmunity, Transplantation and Inflammation Disease Area, Novartis Institutes for Biomedical Research, Basel, Switzerland *Correspondence: Professor Lucy S.K. Walker. Institute of Immunity & Transplantation, Division of Infection & Immunity, University College London, Royal Free Campus, London, UK NW3 2PF. Tel: +44 (0)20 7794 0500 ext 22468. Email: [email protected]. 1 Abstract Therapeutic targeting of immune checkpoints has garnered significant attention in the area of cancer immunotherapy, and efforts have focused in particular on the CD28 family members CTLA-4 and PD-1. In autoimmunity, these same pathways can be targeted to opposite effect, to curb the over- exuberant immune response. The CTLA-4 checkpoint serves as an exemplar, whereby CTLA-4 activity is blocked by antibodies in cancer immunotherapy and augmented by the provision of soluble CTLA-4 in autoimmunity. Here we review the targeting of costimulatory molecules in autoimmune disease, focusing in particular on the CD28 family and TNFR family members. We present the state-of-the-art in costimulatory blockade approaches, including rational combinations of immune inhibitory agents, and discuss the future opportunities and challenges in this field. 2 The risk of autoimmune disease is an inescapable consequence of the manner in which the adaptive immune system operates. To ensure effective immunity against a diverse array of unknown pathogens, antigen recognition systems based on random gene rearrangement and mutagenesis have evolved to anticipate the antigenic universe.
    [Show full text]
  • Adipocytes As Immune Cells: Differential Expression of TWEAK
    Adipocytes as Immune Cells: Differential Expression of TWEAK, BAFF, and APRIL and Their Receptors (Fn14, BAFF-R, TACI, and BCMA) at Different Stages of Normal This information is current as and Pathological Adipose Tissue of September 26, 2021. Development Vassilia-Ismini Alexaki, George Notas, Vassiliki Pelekanou, Marilena Kampa, Maria Valkanou, Panayiotis Theodoropoulos, Efstathios N. Stathopoulos, Andreas Tsapis Downloaded from and Elias Castanas J Immunol published online 14 October 2009 http://www.jimmunol.org/content/early/2009/10/14/jimmuno l.0901186 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2009/10/13/jimmunol.090118 Material 6.DC1 Why The JI? Submit online. by guest on September 26, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published October 14, 2009, doi:10.4049/jimmunol.0901186 The Journal of Immunology Adipocytes as Immune Cells: Differential Expression of TWEAK, BAFF, and APRIL and Their Receptors (Fn14, BAFF-R, TACI, and BCMA) at Different Stages of Normal and Pathological Adipose Tissue Development1 Vassilia-Ismini Alexaki,* George Notas,* Vassiliki Pelekanou,2* Marilena Kampa,* Maria Valkanou,* Panayiotis Theodoropoulos,† Efstathios N.
    [Show full text]
  • Haptoglobin 9D91-20 30-3966/R4
    HAPTOGLOBIN 9D91-20 30-3966/R4 HAPTOGLOBIN This package insert contains information to run the Haptoglobin assay on the ARCHITECT c Systems™ and the AEROSET System. NOTE: Changes Highlighted NOTE: This package insert must be read carefully prior to product use. Package insert instructions must be followed accordingly. Reliability of assay results cannot be guaranteed if there are any deviations from the instructions in this package insert. Customer Support United States: 1-877-4ABBOTT Canada: 1-800-387-8378 (English speaking customers) 1-800-465-2675 (French speaking customers) International: Call your local Abbott representative Symbols in Product Labeling Calibrators 1 through 5 Catalog number/List number Concentration Serial number Authorized Representative in the Consult instructions for use European Community Ingredients Manufacturer In vitro diagnostic medical device Temperature limitation Batch code/Lot number Use by/Expiration date Reagent 1 Reagent 2 ABBOTT LABORATORIES ABBOTT Abbott Park, IL 60064, USA Max-Planck-Ring 2 65205 Wiesbaden Germany +49-6122-580 May 2007 ©2004, 2007 Abbott Laboratories 1 NAME REAGENT HANDLING AND STORAGE HAPTOGLOBIN Reagent Handling Remove air bubbles, if present in the reagent cartridge, with a new INTENDED USE applicator stick. Alternatively, allow the reagent to sit at the appropriate The Haptoglobin assay is used for the quantitation of haptoglobin in storage temperature to allow the bubbles to dissipate. To minimize human serum or plasma. volume depletion, do not use a transfer pipette to remove the bubbles. CAUTION: Reagent bubbles may interfere with proper detection of SUMMARY AND EXPLANATION OF TEST reagent level in the cartridge, causing insufficient reagent aspiration Haptoglobin is a protein synthesized in the liver that binds with the which could impact results.
    [Show full text]
  • BAFF Expression Is Increased in Patients
    g in Geno nin m i ic M s ta & a P Eilertsen, J Data Mining in Genom Proteomics 2012, 3:1 D r f o Journal of o t e l DOI: 10.4172/2153-0602.1000113 o a m n r i c u s o J ISSN: 2153-0602 Data Mining in Genomics & Proteomics Research Article Open Access BAFF Expression is Increased in Patients with Lupus Nephritis and Associated with Antinucleosome Antibodies, C1 Inhibitor, Α-1-Acid- Glycoprotein and Endothelial Activation Markers G. Ø. Eilertsen¹*, M. Van Ghelue² and J.C. Nossent¹ ¹Bone and Joint research group, Department of Health Science, Medical School, University of Tromsø, Norway ²Medical Genetics Department, University Hospital North Norway, Tromsø, Norway Abstract Objectives: B cell activating factor (BAFF) inhibitor therapy has recently been approved for non-renal Systemic Lupus Erythematosus (SLE). While BAFF plays a role in experimental lupus nephritis (LN), its role human LN is not well studied. Methods: Case control study in 102 SLE patients, 30 with LN (+LN) and 72 without LN (-LN) and 31 healthy controls. We analysed BAFF mRNA expression in PBMCs (BAFF-RQ) and serum BAFF (s-BAFF) levels and investigated their relation with clinical, histological- and additional acute phase proteins. Results: s-BAFF and BAFF-RQ were increased in +LN patients compared to controls, but their expression did not correlate with ISN/RPS class, Activity- or Chronicity index on biopsy. s-BAFF correlated with levels of anti-nucleosome antibodies, C1 inhibitor and α-1-acid-glycoprotein (AGP), while BAFF-RQ correlated inversely with Factor VIII.
    [Show full text]
  • Urinary Proteomics for the Early Diagnosis of Diabetic Nephropathy in Taiwanese Patients Authors
    Urinary Proteomics for the Early Diagnosis of Diabetic Nephropathy in Taiwanese Patients Authors: Wen-Ling Liao1,2, Chiz-Tzung Chang3,4, Ching-Chu Chen5,6, Wen-Jane Lee7,8, Shih-Yi Lin3,4, Hsin-Yi Liao9, Chia-Ming Wu10, Ya-Wen Chang10, Chao-Jung Chen1,9,+,*, Fuu-Jen Tsai6,10,11,+,* 1 Graduate Institute of Integrated Medicine, China Medical University, Taichung, 404, Taiwan 2 Center for Personalized Medicine, China Medical University Hospital, Taichung, 404, Taiwan 3 Division of Nephrology and Kidney Institute, Department of Internal Medicine, China Medical University Hospital, Taichung, 404, Taiwan 4 Institute of Clinical Medical Science, China Medical University College of Medicine, Taichung, 404, Taiwan 5 Division of Endocrinology and Metabolism, Department of Medicine, China Medical University Hospital, Taichung, 404, Taiwan 6 School of Chinese Medicine, China Medical University, Taichung, 404, Taiwan 7 Department of Medical Research, Taichung Veterans General Hospital, Taichung, 404, Taiwan 8 Department of Social Work, Tunghai University, Taichung, 404, Taiwan 9 Proteomics Core Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, 404, Taiwan 10 Human Genetic Center, Department of Medical Research, China Medical University Hospital, China Medical University, Taichung, 404, Taiwan 11 Department of Health and Nutrition Biotechnology, Asia University, Taichung, 404, Taiwan + Fuu-Jen Tsai and Chao-Jung Chen contributed equally to this work. Correspondence: Fuu-Jen Tsai, MD, PhD and Chao-Jung Chen, PhD FJ Tsai: Genetic Center, China Medical University Hospital, No.2 Yuh-Der Road, 404 Taichung, Taiwan; Telephone: 886-4-22062121 Ext. 2041; Fax: 886-4-22033295; E-mail: [email protected] CJ Chen: Graduate Institute of Integrated Medicine, China Medical University, No.91, Hsueh-Shih Road, 404, Taichung, Taiwan; Telephone: 886-4-22053366 Ext.
    [Show full text]
  • Expression of Haptoglobin-Related Protein and Its Potential Role As a Tumor Antigen (Neoplasia/Breast Cancer/Acute-Phase Proteins) FRANCIS P
    Proc. Natl. Acad. Sci. USA Vol. 86, pp. 1188-1192, February 1989 Biochemistry Expression of haptoglobin-related protein and its potential role as a tumor antigen (neoplasia/breast cancer/acute-phase proteins) FRANCIS P. KUHAJDA*, ASOKA I. KATUMULUWA, AND GARY R. PASTERNACK Department of Pathology, The Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD 21205 Communicated by M. Daniel Lane, November 14, 1988 (receivedfor review August 3, 1988) ABSTRACT These studies describe the detection of a pensity for tumor invasion and early metastasis. Clinically, haptoglobin species, its characterization as the HPR gene these properties manifested as a dramatically worsened product, and its association with both pregnancy and neopla- prognosis (7-9). In Western blots (immunoblots) of fractions sia. Previous work showed that the early recurrence of human of sera from pregnant women, this antiserum detected a set breast cancer correlated with immunohistochemical staining of proteins whose properties were inconsistent with those of with a commercial antiserum ostensibly directed against preg- PAPP-A, a homotetramer composed of 200-kDa polypep- nancy-associated plasma protein A (PAPP-A). Use of this tides. The studies below describe the purification of the antiserum to guide purification ofthe putative antigen led to the unexpectedly immunoreactive protein species from the present identification and purification of a strongly immuno- plasma ofpregnant women, its identification as the HPR gene reactive protein species distinct from PAPP-A that was present product, and its relationship to the clinically important in the plasma of pregnant women at term. Unlike PAPP-A, a antigen expressed in human breast carcinoma.
    [Show full text]
  • Elevated Alpha-1 Antitrypsin Is a Major Component of Glyca-Associated Risk for Future Morbidity and Mortality
    bioRxiv preprint doi: https://doi.org/10.1101/309138; this version posted April 26, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Elevated alpha-1 antitrypsin is a major component of GlycA-associated risk for future morbidity and mortality Scott C. Ritchie1,2,3,4*, Johannes Kettunen5,6,7, Marta Brozynska1,2,3,4, Artika P. Nath1,8, Aki S. Havulinna6,9, Satu Männisto6, Markus Perola6,9, Veikko Salomaa6, Mika Ala-Korpela5,7,10,11,12,13, Gad Abraham1,2,3,4, Peter Würtz14,15, Michael Inouye1,2,3,4* 1Systems Genomics Lab, Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia 2Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, United Kingdom 3Department of Clinical Pathology, The University of Melbourne, Parkville, VIC 3010, Australia 4School of BioSciences, The University of Melbourne, Parkville, VIC 3010, Australia 5Computational Medicine, Faculty of Medicine, University of Oulu and Biocenter Oulu, Oulu 90014, Finland 6National Institute for Health and Welfare, Helsinki 00271, Finland 7NMR Metabolomics Laboratory, School of Pharmacy, University of Eastern Finland, Kuopio 70211, Finland 8Department of Microbiology and Immunology, The University of Melbourne, Parkville, VIC 3010, Australia 9Institute for Molecular Medicine Finland, University of Helsinki, Helsinki 00014, Finland 10Population Health Science,
    [Show full text]